



Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant *Pseudomonas aeruginosa* and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates

María M. Montero,^a Sandra Domene Ochoa,^a Carla López-Causapé,^b Sonia Luque,^c Luisa Sorlí,^a Núria Campillo,^c Inmaculada López Montesinos,^a Eduardo Padilla,^d Núria Prim,^d Ariadna Angulo-Brunet,^e Santiago Grau,^c Antonio Oliver,^b Juan P. Horcajada^a

^aInfectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain

^bServicio de Microbiología y Unidad de Investigación, Hospital Son Espases, IdISBa, Palma de Mallorca, Spain

^cPharmacy Service, Hospital del Mar, Barcelona, Spain

^dLaboratori de Referència de Catalunya, Barcelona, Spain

^ePsychology and Education Science Studies, Universitat Oberta de Catalunya, Barcelona, Spain

ABSTRACT Ceftazidime-avibactam (CZA) has emerged as a promising solution to the lack of new antibiotics against *Pseudomonas aeruginosa* infections. Data from *in vitro* assays of CZA combinations, however, are scarce. The objective of our study was to perform a time-kill analysis of the effectiveness of CZA alone and in combination with other antibiotics against a collection of extensively drug-resistant (XDR) *P. aeruginosa* isolates. Twenty-one previously characterized representative XDR *P. aeruginosa* isolates were selected. Antibiotic susceptibility was tested by broth microdilution, and results were interpreted using CLSI criteria. The time-kill experiments were performed in duplicate for each isolate. Antibiotics were tested at clinically achievable free-drug concentrations. Different treatment options, including CZA alone and combined with amikacin, aztreonam, meropenem, and colistin, were evaluated to identify the most effective combinations. Seven isolates were resistant to CZA (MIC \geq 16/4 mg/liter), including four metallo- β -lactamase (MBL)-carrying isolates and two class A carbapenemases. Five of them were resistant or intermediate to aztreonam (MIC \geq 16 mg/liter). Three isolates were resistant to amikacin (MIC \geq 64 mg/liter) and one to colistin (MIC \geq 4 mg/liter). CZA monotherapy had a bactericidal effect in 100% (14/14) of the CZA-susceptible isolates. Combination therapies achieved a greater overall reduction in bacterial load than monotherapy for the CZA-resistant isolates. CZA plus colistin was additive or synergistic in 100% (7/7) of the CZA-resistant isolates, while CZA plus amikacin and CZA plus aztreonam were additive or synergistic in 85%. CZA combined with colistin, amikacin, or aztreonam was more effective than monotherapy against XDR *P. aeruginosa* isolates. A CZA combination could be useful for treating XDR *P. aeruginosa* infections, including those caused by CZA-resistant isolates.

IMPORTANCE The emergence of resistance to antibiotics is a serious public health problem worldwide and can be a cause of mortality. For this reason, antibiotic treatment is compromised, and we have few therapeutic options to treat infections. The main goal of our study is to search for new treatment options for infections caused by difficult-to-treat resistant germs. *Pseudomonas aeruginosa* is a Gram-negative bacterium distributed throughout the world with the ability to become resistant to most available antibiotics. Ceftazidime-avibactam (CZA) emerged as a promising solution to the lack of new antibiotics against infections caused by *P. aeruginosa*

Citation Montero MM, Domene Ochoa S, López-Causapé C, Luque S, Sorlí L, Campillo N, López Montesinos I, Padilla E, Prim N, Angulo-Brunet A, Grau S, Oliver A, Horcajada JP. 2021. Time-kill evaluation of antibiotic combinations containing ceftazidime-avibactam against extensively drug-resistant *Pseudomonas aeruginosa* and their potential role against ceftazidime-avibactam-resistant isolates. *Microbiol Spectr* 9:e00585-21. <https://doi.org/10.1128/Spectrum.00585-21>.

Editor William Lainhart, University of Arizona/Banner Health

Copyright © 2021 Montero et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to María M. Montero, 95422@parcdesalutmar.cat, or Juan P. Horcajada, jhorcajada@psmar.cat.

Received 18 June 2021

Accepted 29 June 2021

Published 28 July 2021

strains. This study intended to analyze the effect of CZA alone or in combination with other available antibiotics against *P. aeruginosa* strains. The combination of CZA with other antibiotics could be more effective than monotherapy against extensively drug-resistant *P. aeruginosa* strains.

KEYWORDS ceftazidime-avibactam, colistin, aztreonam, amikacin, combination therapy, *Pseudomonas aeruginosa*

New therapeutic options for multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Pseudomonas aeruginosa* infections are required to overcome the growing problem of antimicrobial resistance. According to the U.S. Centers for Disease Control and Prevention, XDR *P. aeruginosa* is a “serious threat” to human health, and resistance is on the rise (1). This bacterium has a nonclonal epidemic population structure (2) and can develop antibiotic resistance through several mechanisms. XDR *P. aeruginosa* high-risk clones are disseminated in hospitals around the world (2) and pose a major public health problem because of limited treatment options and rising costs. Sequence type 111 (ST111) and ST235 are the predominant high-risk clones worldwide, but in Spain, the predominant clone is ST175 (2). High-risk clones are frequently responsible for nosocomial infections and are associated with the acquisition of horizontally transferable beta-lactamases and resistance mechanisms through chromosomal mutations (2, 3).

The problem of increasing antimicrobial resistance is compounded by a dwindling supply of new drugs. Given the few antibiotics in the clinical pipeline before 2010, the treatment options for XDR *P. aeruginosa* infections were suboptimal and consisted largely of antibiotics with a narrow therapeutic window and high toxicity (aminoglycosides, polymyxins) or unpredictable pharmacokinetics (colistin), yielding poor patient outcomes (4–7).

Ceftazidime-avibactam (CZA) was approved by the U.S. Food and Drug Administration in 2015 and was the first β -lactam combination to provide broad coverage against XDR Gram-negative pathogens, including *P. aeruginosa* (8). Few studies, however, have examined the effectiveness of CZA against infections caused by XDR *P. aeruginosa* high-risk clones. An *in vitro* study of a large collection of *P. aeruginosa* strains reported a CZA resistance rate of 2.9% (9). Most studies, however, have reported higher rates, up to 18% in some cases (10) and over 50% when XDR strains are involved (11, 12). Strains carrying metallo- β -lactamases (MBLs) have the highest resistance rates (>95%) as they are resistant to CZA, and CZA is not expected to be efficacious against these strains (13).

The use of CZA to treat *P. aeruginosa* infections caused by XDR high-risk clones may be clinically more effective and less toxic than colistin, which is often the only option available (14). However, given the high risk for the emergence of CZA-resistant mutants, it is paramount to monitor their selection during treatment and to evaluate associated risk factors. Combination therapy is a useful strategy for achieving maximum antimicrobial activity against various resistant organisms and for preventing antibiotic resistance (15). *In vitro* experiments have shown synergy for certain antipseudomonal antibiotics against MDR *P. aeruginosa* (5, 15–20). *In vitro* studies evaluating the activity of CZA combined with other antibiotics against *P. aeruginosa*, however, are lacking, and only few reports covering a small number of isolates have been published (21).

The aim of this study was to perform a comprehensive time-kill analysis of CZA alone or in combination with standard antipseudomonal antibiotics against a representative collection of the most common resistance mechanisms and XDR *P. aeruginosa* clones, including high-risk clones.

RESULTS

Antimicrobial susceptibility testing. The antibiotic susceptibility profiles and previously characterized antibiotic resistance mechanisms of the 21 XDR *P. aeruginosa* isolates are shown in Table 1. Seven isolates were resistant to both CZA (MIC \geq 16/4 mg/liter) and meropenem (MIC \geq 8 mg/liter), and of these, four were resistant and one was intermediate

TABLE 1 Antibiotic susceptibility profile and resistance mechanisms of the 21 XDR *P. aeruginosa* isolates^a

Isolate	ST	Acquired β -lactamase(s)	AmpC hyperproduction	OprD deficiency	MIC (mg/liter)				
					AMK	ATM	MEM	CST	CZA
04-017	111	OXA-46	Yes	No	4	64	32	2	8
04-025	175		Yes	Yes	4	16	16	1	4
10-023	175		Yes	Yes	4	16	16	2	4
06-014	179	OXA-10	Yes	Yes	8	16	32	2	4
12-003	244		Yes	Yes	8	32	32	2	4
09-011	274		Yes	Yes	128	64	32	1	4
09-007	313		Yes	Yes	8	32	16	2	4
10-017	395		Yes	No	4	32	8	2	4
06-035	455		Yes	No	<2	64	>32	0.5	8
10-019	2221		Yes	Yes	<2	64	32	2	8
06-025	2534		Yes	Yes	<2	64	8	2	8
06-027	2535		Yes	No	8	32	8	2	4
06-001	2536		Yes	Yes	8	64	32	2	8
09-012	175		Yes	Yes	8	64	16	2	8
10-009	111	VIM-2	Yes	Yes	32	>128	>32	4	>32
07-016	175	GES-5	No	Yes	16	16	>32	2	32
12-012	175	VIM-20, OXA-2	No	Yes	16	8	>32	2	32
07-004	235	GES-19, OXA-2	No	Yes	128	128	>32	2	>32
06-042	235	VIM-47	No	No	64	32	>32	2	32
01-008	253	VIM-1	No	Yes	8	4	>32	2	>32
10-021	2533		Yes	Yes	<2	64	32	1	16

^aMICs (mg/liter) of the following antibiotics tested in this study are shown: amikacin (AMK), aztreonam (ATM), meropenem (MEM), colistin (CST), and ceftazidime-avibactam (CZA). CZA-resistant isolates are highlighted in gray.

to aztreonam (MIC \geq 16 mg/liter), three were resistant to amikacin (MIC \geq 64 mg/liter), and one was resistant to colistin (MIC \geq 4 mg/liter). Six of the seven CZA-resistant isolates harbored carbapenemases belonging to Ambler class A or B and had OprD deficiency, except for one, and two of them showed AmpC hyperproduction.

Time-kill studies. Bacterial growth without antibiotic reached 8 to 9 log₁₀ CFU/ml at 24 h for all isolates. The results of the time-kill experiments for the 21 XDR *P. aeruginosa* isolates are shown in Table S1 in the supplemental material. The mean bacterial loads (log₁₀ CFU/ml) over 24 h for the seven CZA-resistant XDR *P. aeruginosa* isolates treated with each antibiotic regimen are shown in Fig. 1. Table 2 shows the synergistic and additive effects of each combination against CZA-susceptible and CZA-resistant isolates. Table S2 shows the time-kill results (log difference at 24 h) for each antibiotic compared with the control and for each antibiotic combination compared with each antibiotic.

Single antibiotics (aztreonam, meropenem, colistin, amikacin) were not bactericidal against any of the isolates at 24 h. Despite this, when compared with the control, all single antibiotics resulted in fewer bacteria than the control ($F_{4, 64} = 8.7$, $P < 0.001$; amikacin dif = -1.34, $t = -2.5$, $P = 0.02$; aztreonam dif = -1.43, $t = -2.63$, $P = 0.01$; meropenem dif = -1.42, $t = -2.62$, $P = 0.01$; colistin dif = -3.18, $t = -5.87$, $P < 0.001$).

CZA monotherapy was bactericidal against all the CZA-susceptible isolates, with a mean reduction of 3.19 log₁₀ CFU/ml. In a comparison of the effects of the combination of CZA with other antibiotics, we found differences ($F_{4, 65} = 11.08$, $P < 0.001$). CZA plus amikacin (dif = -1.74, $t = -3.58$, $P < 0.001$) and CZA plus colistin (dif = -1.59, $t = -3.25$, $P = 0.001$) achieved a mean reduction of >4 log₁₀ CFU/ml in the same isolates. The best combination against the CZA-susceptible isolates was CZA plus amikacin, which was synergistic or additive in approximately 80% of cases. On the other hand, no differences between CZA alone and CZA with aztreonam were found (dif = -0.48, $t = -0.99$, $P = 0.33$). Furthermore, combining CZA with meropenem increased the number of bacteria in comparison with CZA alone (dif = 1.02, $t = 1.09$, $P = 0.04$).

CZA combination therapies achieved a higher overall reduction in bacterial load than any of the treatments in isolation for the seven CZA-resistant isolates ($F_{1, 61} = 33.92$, $P < 0.001$). The log₁₀ CFU/ml mean for the treatments in isolation was 0.94, and combining




FIG 1 Bacterial load (\log_{10} CFU/ml) over 24 h in the seven CZA-resistant XDR *P. aeruginosa* isolates for each antibiotic regimen. LOD, lower limit of detection.

treatments reduced that mean to 3.44 ($t = -5.82, P < 0.001$). Hence, the mean reduction was 4.4 \log_{10} CFU/ml for CZA plus colistin, amikacin, or aztreonam. As can be seen in Table 2, CZA plus colistin was either additive or synergistic in 100% of cases, while CZA plus amikacin or aztreonam was additive or synergistic in 85% of cases. The combination of CZA with aztreonam was effective against three of the four MBL-carrying isolates and against the two isolates that harbored class A carbapenemases.

DISCUSSION

We investigated the use of CZA alone or in combination with four antibiotics to assess the potential synergistic effects against XDR *P. aeruginosa*. As expected, a bactericidal effect was observed for CZA monotherapy in all the CZA-susceptible *P. aeruginosa* isolates, which had AmpC hyperproduction and/or OprD deficiency. To preserve the effectiveness of CZA, its clinical use should be avoided in naturally resistant strains and in those carrying MBLs and certain class D β -carbapenemases (22). Combination

TABLE 2 Synergistic and additive effects of each antibiotic combination against CZA-susceptible and CZA-resistant *P. aeruginosa* isolates^a

Antibiotic combination	% of isolates					
	CZA susceptible			CZA resistant		
	Synergy	Additivity	Total	Synergy	Additivity	Total
AMK+CZA	8	3	78.6	5	1	85.7
ATM+CZA	2	4	42.9	4	2	85.7
MEM+CZA	1	1	14.3	2	0	28.6
CST+CZA	6	2	57.1	6	1	100.0

^aAMK, amikacin; ATM, aztreonam; MEM, meropenem; CST, colistin; CZA, ceftazidime-avibactam.

therapy has an important role in these clinical scenarios, and CZA combined with other antibacterial agents should be considered.

CZA resistance has already been described in Gram-negative bacilli. β -Lactamase-related mutations are the main mechanism behind CZA resistance in *Enterobacteriales*. Recent reports suggest that the development of different resistance mechanisms within the course of treatment (e.g., mutations in KPC-encoding genes) might threaten the effectiveness of CZA (23, 24), a phenomenon that could be further complicated by horizontal spread (25). The development of CZA resistance during treatment of *P. aeruginosa* infections is frequently due to the selection of mutations in the AmpC β -lactamase structure, which are associated with coresistance with ceftolozane-tazobactam (16). Other contributory factors might be diminished outer membrane permeability and/or overexpression of efflux pumps (26). High-level resistance to CZA might also be due to MBL acquisition (27). Overall, six of the seven CZA-resistant isolates in our study harbored acquired β -lactamases, including several MBLs (VIM type) and a serine carbapenemase.

Little has been published on antibiotic combinations containing CZA, especially in the context of XDR *P. aeruginosa* isolates. Combination therapy with CZA plus aztreonam, amikacin, colistin, fosfomycin, and meropenem was recently evaluated in MDR *Klebsiella pneumoniae* and *P. aeruginosa* strains, but none of the isolates carried MBLs and few time-kill curves were analyzed (28). A synergistic effect was also reported for the combined use of CZA and colistin against MDR *P. aeruginosa* strains, including those resistant to colistin (29). In the present study, the combination of CZA with colistin showed a synergistic or additive effect against all the CZA-resistant *P. aeruginosa* isolates, including a colistin-resistant strain. Synergy was also observed against 85% of these isolates when CZA was combined with amikacin or aztreonam. In the combination of CZA with colistin, several bacterial isolates reached bacterial eradication at 4 and 8 h but then showed a little regrowth at 24 h. The phenomenon of bacterial regrowth could be due to either a loss of functionality of these antibiotics or selection of resistant isolates. Presumably, the latter could include selection of preexisting resistant subpopulations, *de novo* mutations, adaptive resistance, or formation of persistent cells (30). Further studies are required in order to evaluate these possibilities.

A double β -lactam strategy has been tested against carbapenemase-producing enterobacterial isolates in which CZA combined with meropenem or imipenem showed synergy against certain KPC-producing *K. pneumoniae* strains (31). In our study, however, CZA plus meropenem was the only combination to show no synergistic or additive activity against most XDR *P. aeruginosa* isolates. This could be because nonenzymatic mechanisms, alongside acquired β -lactamases, may have contributed to high meropenem MICs in the CZA-resistant isolates.

As mentioned, CZA is not active against MBL-bearing strains (22). The addition of aztreonam might overcome this resistance, as MBLs are known to have a weak hydrolysis capacity against aztreonam (32, 33). Combination therapy with ceftazidime and aztreonam may also be beneficial due to the simultaneous inhibition of multiple

penicillin-binding proteins (34). Additionally, CZA plus aztreonam could exert an independent effect by acting on the “divisome” of Gram-negative bacteria (27). A recent report based on time-kill experiments with five *P. aeruginosa* isolates resistant to both CZA and aztreonam found that the combined use of the antibiotics had a synergistic effect and restored bactericidal activity in four of the isolates (21). In our study, this combination was effective against three of the four MBL-carrying isolates.

This study had some limitations. Our results are based on short *in vitro* assays with minimal antibiotic exposure compared with other pharmacokinetic/pharmacodynamic studies. Since these results are not representative of clinical guidelines for the administration of most antibiotics, they must be validated in *in vivo* experiments (35). The experimental design of this type of study does not allow identification of mechanisms of interactions or taking the emergence of resistance into consideration. A strength of our study is that our results are based on a large number of time-kill assays and show evidence of synergistic or additive effects in a considerable proportion of cases.

In conclusion, CZA is effective against XDR *P. aeruginosa* isolates both alone and in combination with other antibiotics. Combination regimens featuring CZA may be a good option against infections caused by these difficult-to-treat bacteria. Our data support the potential use of CZA in combination with amikacin, aztreonam, and colistin against XDR *P. aeruginosa* isolates, including CZA-resistant isolates and prevalent high-risk clones. These findings may help identify strategies to improve the clinical management of XDR *P. aeruginosa* infections using currently available drugs.

MATERIALS AND METHODS

Bacterial isolates and resistance mechanisms. We studied 21 XDR *P. aeruginosa* clinical isolates which had been previously collected by our group as a part of the COLIMERO trial, a multicenter Spanish trial involving the molecular characterization of 150 XDR *P. aeruginosa* isolates from nine Spanish hospitals using pulsed-field gel electrophoresis, multilocus sequence typing, and whole-genome sequencing (3). The 21 isolates were representative of the clones and the most prevalent and relevant resistance mechanisms detected in the trial, namely, chromosomal mutations (AmpC hyperproduction and OprD inactivation) and horizontally acquired enzymes, including several MBLs and class A carbapenemases.

Antibiotics. The antipseudomonal antibiotics used in the experiments were amikacin, aztreonam, colistin, meropenem (Sigma-Aldrich), and CZA (Pfizer). The antibiotics were chosen based on the mechanism of action and availability in the hospital’s pharmacy. Antibiotic solutions were prepared according to CLSI guidelines (36). Antibiotic concentrations for time-kill experiments were based on area-under-the-curve (AUC) serum levels: for amikacin, 1 g every 24 h (q24h), with an area under the concentration-time curve for 24 h (AUC_{24}) of $196 \mu\text{g} \cdot \text{h/ml}$ (37, 38); for aztreonam, 2 g q8h, with an AUC_{24} of $1,050 \mu\text{g} \cdot \text{h/ml}$ (39); for meropenem, 2 g q8h, with an AUC_{24} of $425 \mu\text{g} \cdot \text{h/ml}$ (40); for colistin, 4.5 MIU (million International units) q12h, with an AUC_{24} of $50 \mu\text{g} \cdot \text{h/ml}$ (41, 42); for CZA, 2 g q8h, with an AUC_{24} of $800 \mu\text{g} \cdot \text{h/ml}$ (43); and for avibactam, 2 g q8h, with an AUC_{24} of $147 \mu\text{g} \cdot \text{h/ml}$ (43).

Antibiotic susceptibility testing. The susceptibility profiles of the XDR isolates were obtained from the COLIMERO trial (3). Antimicrobial susceptibility was tested using broth microdilution and agar dilution methods with cation-adjusted Mueller-Hinton II broth (CAMHB) and Mueller-Hinton (MH) agar media, according to the CLSI guidelines (36). Ceftazidime susceptibility testing was conducted alone and in combination with a fixed avibactam concentration (4 mg/liter).

Time-kill experiments. Time-kill studies were performed to analyze the activity of the selected antibiotics alone and in combination with CZA at clinically achievable free-drug concentrations. All experiments were performed in duplicate. An overnight culture of isolate was diluted with CAMHB and further incubated at 37°C for an hour to reach early log-phase growth. The bacterial suspension was diluted with CAMHB according to the absorbance at 630 nm. The magnitudes of absorbance ranged from 0.2 to 0.4. Sterile 50-ml conical flasks were used with 30 ml of CAMHB supplemented with the corresponding antibiotics. The final bacterial inoculum was approximately 6 to 7 \log_{10} CFU/ml per flask. Flasks were incubated at 37°C in a shaker water bath for 24 h. Samples were collected at 0, 4, 8, and 24 h to measure bacterial growth. A 1-ml aliquot was obtained from each flask at each time point, centrifuged at 13,000 rpm for 3 min, and reconstituted with sterile saline solution to its original volume to minimize drug carryover. Serial decimal dilutions in CAMHB were performed; MH agar plates were inoculated (200 μl per plate) and incubated in a humidified incubator (37°C) for 18 to 24 h. Bacterial colonies for each sample were counted after overnight incubation. The bacterial density from the original sample was calculated based on the dilution factor. The limit of detection (LOD) was $1.3 \log_{10}$ CFU/ml.

Apart from describing the results, in order to assess the effect of monotherapy and of the antibiotic combinations, we performed a series of regression analyses in which we entered the log difference in 24 h as dependent variable and each antibiotic regimen as independent variable. We checked for the application conditions of the regression, and all the conditions were met (normality of the residuals [assessed with Shapiro-Wilk’s test] and homoscedasticity [assessed with the Breusch-Pagan test]).

Pharmacodynamic time-kill parameters. The results of the time-kill experiments were read at the different time points (0, 4, 8, and 24 h). Bactericidal activity was defined as a $\geq 3\text{-log}_{10}$ CFU/ml reduction, synergy as a $\geq 2\text{-log}_{10}$ CFU/ml reduction for a given combination compared with the most active single agent, additivity as a 1- to 2-log_{10} CFU/ml reduction in the final colony count for the combination compared with the most active single agent, and antagonism as a regrowth to $\geq 1\text{-log}_{10}$ CFU/ml for the combination compared with the least active single agent (44, 45). In addition to the aforementioned relevance criteria, we applied regression analysis to determine if the difference in \log_{10} was statistically significant.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.3 MB.

ACKNOWLEDGMENTS

We thank the Institute for Clinical Pharmacodynamics (ICPD), Schenectady, NY, and the Infectious Pathology and Antimicrobials Research Group (IPAR), Instituto Hospital del Mar d'Investigacions Mèdiques (IMIM), for their support.

This study was supported by a medical grant from Pfizer Spain and was partially supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, FEDER PI16/00669, PI17/00251, and PI18/0076, and the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016).

We declare no conflicts of interest.

REFERENCES

1. Noval M, Banoub M, Claeys KC, Heil E. 2020. The battle is on: new beta-lactams for the treatment of multidrug-resistant Gram-negative organisms. *Curr Infect Dis Rep* 22:1. <https://doi.org/10.1007/s11908-020-0710-9>.
2. Oliver A, Mulet X, López-Causapé C, Juan C. 2015. The increasing threat of *Pseudomonas aeruginosa* high-risk clones. *Drug Resist Updat* 21–22:41–59. <https://doi.org/10.1016/j.drup.2015.08.002>.
3. del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverría C, Dueñas C, Aystarán I, Zamorano L, Martínez-Martínez L, Horcajada JP, Oliver A. 2017. Genomics and susceptibility profiles of extensively drug-resistant *Pseudomonas aeruginosa* isolates from Spain. *Antimicrob Agents Chemother* 61:e01589-17. <https://doi.org/10.1128/AAC.01589-17>.
4. Horcajada JP, Sorlí L, Luque S, Benito N, Segura C, Campillo N, Montero M, Esteve E, Mirelis B, Pomar V, Cuquet J, Martí C, Garro P, Grau S. 2016. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. *Int J Antimicrob Agents* 48:725–727. <https://doi.org/10.1016/j.ijantimicag.2016.08.020>.
5. Montero MM, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Segura C, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP. 2019. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant *Pseudomonas aeruginosa*, including high-risk clones. *J Glob Antimicrob Resist* 18:37–44. <https://doi.org/10.1016/j.jgar.2019.04.012>.
6. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. 2013. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. *Antimicrob Agents Chemother* 57:5104–5111. <https://doi.org/10.1128/AAC.01230-13>.
7. Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. 2013. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. *BMC Infect Dis* 13:380. <https://doi.org/10.1186/1471-2334-13-380>.
8. U.S. Food and Drug Administration. 2016. Novel drugs summary 2015. U.S. Food and Drug Administration, Washington, DC.
9. Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. 2017. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* isolates from U.S. medical centers, 2013 to 2016. *Antimicrob Agents Chemother* 61:e01045-17. <https://doi.org/10.1128/AAC.01045-17>.
10. Gonzalez MD, McMullen AR, Wallace MA, Crotty MP, Ritchie DJ, Burnham C-AD. 2017. Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of β -lactam-resistant Gram-negative bacteria. *Ann Lab Med* 37:174–176. <https://doi.org/10.3343/alm.2017.37.2.174>.
11. Schaumburg F, Bletz S, Mellmann A, Becker K, Idelevich EA. 2019. Comparison of methods to analyse susceptibility of German MDR/XDR *Pseudomonas aeruginosa* to ceftazidime/avibactam. *Int J Antimicrob Agents* 54:255–260. <https://doi.org/10.1016/j.ijantimicag.2019.05.001>.
12. Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. 2017. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant *Pseudomonas aeruginosa* isolates. *Antimicrob Agents Chemother* 61:e01858-17. <https://doi.org/10.1128/AAC.01858-17>.
13. Karlowsky JA, Kazmierczak KM, Bouchillon SK, De Jonge BLM, Stone GG, Sahm DF. 2018. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and *Pseudomonas aeruginosa* collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015. *Antimicrob Agents Chemother* 62:e02569-17. <https://doi.org/10.1128/AAC.02569-17>.
14. Montero M, Horcajada JP, Sorlí L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H. 2009. Effectiveness and safety of colistin for the treatment of multidrug-resistant *Pseudomonas aeruginosa* infections. *Infection* 37:461–465. <https://doi.org/10.1007/s15010-009-8342-x>.
15. Montero M, VanScoy BD, López-Causapé C, Conde H, Adams J, Segura C, Zamorano L, Oliver A, Horcajada JP, Ambrose PG. 2018. Evaluation of ceftolozane-tazobactam in combination with meropenem against *Pseudomonas aeruginosa* sequence type 175 in a hollow-fiber infection model. *Antimicrob Agents Chemother* 62:e00026-18. <https://doi.org/10.1128/AAC.00026-18>.
16. Fraile-Ribot PA, Cabot G, Mulet X, Periañez L, Luisa Martín-Pena M, Juan C, Pérez JL, Oliver A. 2018. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 73:658–663. <https://doi.org/10.1093/jac/dkx424>.
17. Montero M, Ochoa SD, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Angulo-Brunet A, Padilla E, Prim N, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP. 2020. Efficacy of ceftolozane-tazobactam in combination with colistin against extensively drug-resistant *Pseudomonas aeruginosa*, including high-risk clones, in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother* 64:e02542-19. <https://doi.org/10.1128/AAC.02542-19>.
18. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. 2003. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother* 47:905–909. <https://doi.org/10.1128/AAC.47.3.905-909.2003>.

19. Cai Y, Yang D, Wang J, Wang R. 2018. Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent *Pseudomonas aeruginosa* intraperitoneal murine infection model. *J Antimicrob Chemother* 73:456–461. <https://doi.org/10.1093/jac/dkx399>.
20. Louie A, Grasso C, Bahniuk N, B VS, Brown DL, Kulawy R, Drusano GL. 2010. The combination of meropenem and levofloxacin is synergistic with respect to both *Pseudomonas aeruginosa* kill rate and resistance suppression. *Antimicrob Agents Chemother* 54:2646–2654. <https://doi.org/10.1128/AAC.00065-10>.
21. Lee M, Abbey T, Biagi M, Wenzler E. 2021. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo- β -lactamase-producing *Pseudomonas aeruginosa*. *Diagn Microbiol Infect Dis* 99:115227. <https://doi.org/10.1016/j.diagmicrobio.2020.115227>.
22. Wang Y, Wang J, Wang R, Cai Y. 2020. Resistance to ceftazidime-avibactam and underlying mechanisms. *J Glob Antimicrob Resist* 22:18–27. <https://doi.org/10.1016/j.jgar.2019.12.009>.
23. Compain F, Arthur M. 2017. Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 β -lactamase. *Antimicrob Agents Chemother* 61:e00451-17. <https://doi.org/10.1128/AAC.00451-17>.
24. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing *Klebsiella pneumoniae* isolate. *Antimicrob Agents Chemother* 59:6605–6607. <https://doi.org/10.1128/AAC.01165-15>.
25. Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. 2017. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β -lactamases. *Antimicrob Agents Chemother* 61:e02534-16. <https://doi.org/10.1128/AAC.02534-16>.
26. Winkler ML, Papp-Wallace KM, Hujer AM, Domitrovic TN, Hujer KM, Hurless KN, Tuohy M, Hall G, Bonomo RA. 2015. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 59:1020–1029. <https://doi.org/10.1128/AAC.04238-14>.
27. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, Van Duijn D, Kreiswirth BN, Chambers HF, Fowler VG, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. 2017. Can ceftazidime-avibactam and aztreonam overcome β -lactam resistance conferred by metallo- β -lactamases in Enterobacteriaceae? *Antimicrob Agents Chemother* 61:e02243-16. <https://doi.org/10.1128/AAC.02243-16>.
28. Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, Rybak MJ. 2019. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomicin against well-characterized multidrug-resistant *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 63:e00779-19. <https://doi.org/10.1128/AAC.00779-19>.
29. Mataraci Kara E, Yilmaz M, Istanbulu Tosun A, Özbek Çelik B. 2020. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of *Pseudomonas aeruginosa*. *Infect Dis (Lond)* 52:616–624. <https://doi.org/10.1080/23744235.2020.1767803>.
30. Fernández L, Breidenstein EBM, Hancock REW. 2011. Creeping baselines and adaptive resistance to antibiotics. *Drug Resist Updat* 14:1–21. <https://doi.org/10.1016/j.drug.2011.01.001>.
31. Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, Viale PL, Re MC, Ambretti S. 2017. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing *Klebsiella pneumoniae* clinical isolates. *Int J Infect Dis* 65:1–3. <https://doi.org/10.1016/j.ijid.2017.09.017>.
32. Sy S, Zhuang L, Xia H, Beaudoin M-E, Schuck VJ, Derendorf H. 2017. Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms. *CPT Pharmacometrics Syst Pharmacol* 6:197–207. <https://doi.org/10.1002/psp4.12159>.
33. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N. 2012. Characterization of β -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline/avibactam (NXL104). *J Antimicrob Chemother* 67:1354–1358. <https://doi.org/10.1093/jac/dks079>.
34. Asli A, Brouillette E, Krause KM, Nichols WW, Malouin F. 2016. Distinctive binding of avibactam to penicillin-binding proteins of gram-negative and gram-positive bacteria. *Antimicrob Agents Chemother* 60:752–756. <https://doi.org/10.1128/AAC.02102-15>.
35. Tängdén T, Karvanen M, Friberg LE, Odenholt I, Cars O. 2017. Assessment of early combination effects of colistin and meropenem against *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in dynamic time-kill experiments. *Infect Dis (Lond)* 49:521–527. <https://doi.org/10.1080/23744235.2017.1296183>.
36. CLSI. 2020. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI, Wayne, PA.
37. Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahezdadeh M. 2013. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. *Eur Rev Med Pharmacol Sci* 17:285–291.
38. de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonnevile R. 2014. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. *Intensive Care Med* 40:998–1005. <https://doi.org/10.1007/s00134-014-3276-x>.
39. Smith PF, Ballou CH, Booker BM, Forrest A, Schentag JJ. 2001. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. *Clin Ther* 23:1231–1244. [https://doi.org/10.1016/S0149-2918\(01\)80103-X](https://doi.org/10.1016/S0149-2918(01)80103-X).
40. Tam VH, Nikolaou M. 2011. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. *PLoS Comput Biol* 7:e1001043. <https://doi.org/10.1371/journal.pcbi.1001043>.
41. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. *Antimicrob Agents Chemother* 53:3430–3436. <https://doi.org/10.1128/AAC.01361-08>.
42. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. *Antimicrob Agents Chemother* 55:3284–3294. <https://doi.org/10.1128/AAC.01733-10>.
43. Das S, Zhou D, Nichols WW, Townsend A, Newell P, Li J. 2020. Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia. *Eur J Clin Pharmacol* 76:349–361. <https://doi.org/10.1007/s00228-019-02804-z>.
44. Gómez-Junyent J, Benavent E, Sierra Y, El Haj C, Soldevila L, Torrejón B, Rigo-Bonnin R, Tubau F, Ariza J, Murillo O. 2019. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant *Pseudomonas aeruginosa* in an in vitro biofilm pharmacodynamic model. *Int J Antimicrob Agents* 53:612–619. <https://doi.org/10.1016/j.ijantimicag.2019.01.010>.
45. Lim TP, Cai Y, Hong Y, Chan ECY, Suranthran S, Teo JQM, Lee WH, Tan TY, Hsu LY, Koh TH, Tan TT, Kwa ALH. 2015. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 59:2515–2524. <https://doi.org/10.1128/AAC.03639-14>.